Background: Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However. only about 20% of NSCLC patients can benefit from this treatment. At present. https://www.roneverhart.com/Jouer-Soft-Focus-Hydrate-Set-Powder/